<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-54 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-54</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-54</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <p><strong>Paper ID:</strong> paper-fcc794d59b6567b127253557b5b02bda2e201484</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/fcc794d59b6567b127253557b5b02bda2e201484" target="_blank">Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing</a></p>
                <p><strong>Paper Venue:</strong> Cell</p>
                <p><strong>Paper TL;DR:</strong> Exome and genome sequences and whole-genome sequence analysis revealed frequent structural rearrangements, including in-frame exonic alterations within EGFR and SIK2 kinases, which are attractive targets for biological characterization and therapeutic targeting of lung adenocarcinoma.</p>
                <p><strong>Cost:</strong> 0.022</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e54.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e54.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR Ex25-26 del</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR exons 25 and 26 C-terminal deletion (EGFR Ex25&26 deletion)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A novel in-frame deletion removing EGFR exons 25 and 26 that truncates the C-terminal tail, discovered by WGS and shown here to be oncogenic and TKI-sensitive in cellular models.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>183 primary, mostly chemotherapy-naive lung adenocarcinoma tumor/normal pairs (159 WES, 24 WGS, 1 WGS only). Cohort included never-smokers (27), light smokers (17), heavy smokers (118), and 21 unknown; multiple stages represented. One WGS tumor harboring this event was a metastatic post-chemotherapy sample (LU-A08-43).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>definition_of_driver_negative</strong></td>
                            <td>The paper defines driver activation for dominant oncogenes by presence of COSMIC hotspot mutations (≥10 occurrences) or high-level focal amplification, and considers tumors 'driver-negative' when they lack such activating events in known proliferative signaling genes (e.g., EGFR, KRAS, BRAF, ALK, RET, ROS1, ERBB2).</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_fraction</strong></td>
                            <td>The authors report that 47% of tumors harbored a mutation in a known proliferative signaling driver; therefore ~53% lacked such a mutation (and ~45% lacked such alterations even when including high-level amplifications, since including amplifications raised the fraction with drivers to 55%).</td>
                        </tr>
                        <tr>
                            <td><strong>assay_and_platforms</strong></td>
                            <td>Whole-exome sequencing (WES; median 92x coverage for tumor), whole-genome sequencing (WGS; median tumor coverage 69x), and SNP arrays for copy-number; paired tumor/normal sequencing; WGS paired-end and split-read mapping used to detect rearrangement breakpoints. Functional follow-up used ectopic expression in NIH 3T3 and Ba/F3 cells, immunoblotting, soft-agar colony assays, and drug sensitivity assays.</td>
                        </tr>
                        <tr>
                            <td><strong>candidate_driver_event</strong></td>
                            <td>In-frame EGFR C-terminal deletion removing exons 25 and 26 (EGFR v-like C-terminal truncation)</td>
                        </tr>
                        <tr>
                            <td><strong>event_class</strong></td>
                            <td>structural variant/rearrangement (in-frame deletion affecting coding exons)</td>
                        </tr>
                        <tr>
                            <td><strong>genes_and_pathways_implicated</strong></td>
                            <td>EGFR → RTK/MAPK and PI3K/AKT signaling (RTK family; canonical EGFR oncogene)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative_subset</strong></td>
                            <td>Observed in a single WGS tumor; this tumor also harbored a concurrent EGFR p.G719S mutation (i.e., not strictly driver-negative). Exact count among driver-negative tumors not provided.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_overall_luad</strong></td>
                            <td>Observed once in this cohort (1/183; ~0.5% overall in this dataset).</td>
                        </tr>
                        <tr>
                            <td><strong>mutual_exclusivity_or_cooccurrence</strong></td>
                            <td>Co-occurred with another activating EGFR mutation (p.G719S) in the same tumor, suggesting possible co-occurrence or subclonal events rather than exclusivity with other drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type_for_driver_status</strong></td>
                            <td>WGS detection of an in-frame coding deletion; structural mapping of breakpoints; prior literature documenting oncogenic C-terminal EGFR deletions in glioblastoma; statistical novelty and manual annotation; direct functional evidence provided in vitro.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_validation</strong></td>
                            <td>Ectopic expression of EGFR Δex25-26 in NIH 3T3 cells induced soft-agar colony formation (ligand-independent), increased EGFR and AKT phosphorylation in absence of EGF, and conferred IL-3-independent growth in Ba/F3 cells. Ba/F3 proliferation driven by the mutant was inhibited by erlotinib (dose-response reported). Experiments repeated multiple times (representative results shown).</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications_and_response</strong></td>
                            <td>Mutant EGFR-driven Ba/F3 cells were sensitive to the EGFR tyrosine kinase inhibitor erlotinib in vitro, implying potential responsiveness to EGFR inhibitors; no clinical treatment data provided in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>omics_signatures_in_driver_negative_tumors</strong></td>
                            <td>Not specifically profiled for this single event; paper notes mutation-spectrum clusters and that many tumors lack canonical proliferative drivers, motivating search for structural and epigenetic/RNA regulatory drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_signatures</strong></td>
                            <td>This specific tumor was from the WGS set; the paper does not state its exact TMB separately here. Cohort-wide: mean exonic somatic mutation rate ~11.9 mutations/Mb; smokers had significantly higher rates than never-smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>histologic_or_clinical_associations</strong></td>
                            <td>No histologic subtype, smoking status, or prognosis associations specifically reported for this EGFR C-terminal deletion within the paper beyond co-occurrence with p.G719S in the same tumor.</td>
                        </tr>
                        <tr>
                            <td><strong>alternative_explanations_or_limitations</strong></td>
                            <td>The tumor also harbored an EGFR p.G719S mutation, complicating interpretation of which alteration is the dominant driver; single-case observation limits generality. WGS enabled detection, but WES or targeted panels lacking WGS/split-read analysis might miss such events.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_model</strong></td>
                            <td>Removal of the EGFR C-terminal tail relieves autoinhibitory constraints and/or disrupts regulatory interaction motifs (e.g., CBL-binding), producing constitutive EGFR kinase activation, downstream AKT activation, ligand-independent proliferation, and sensitivity to EGFR TKIs.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e54.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e54.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SIK2 dup</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SIK2 in-frame kinase domain duplication</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An in-frame duplication that duplicates a portion of SIK2 including sequence upstream of the activation Thr-175 site, discovered by WGS and validated by qPCR; proposed as a potential activating structural event in a tumor lacking canonical oncogene mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Same 183 LUAD cohort with 24 WGS profiled for rearrangements; the SIK2 event was identified via WGS analysis of rearrangements and validated by qPCR in the WGS subset.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>definition_of_driver_negative</strong></td>
                            <td>Paper considers tumors 'driver-negative' when lacking activating hotspot mutations or focal amplifications in canonical dominant oncogenes; SIK2 was reported in tumors 'without mutations in lung adenocarcinoma oncogenes.'</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_fraction</strong></td>
                            <td>Not explicitly enumerated for SIK2; the event was reported among the WGS cases and described as occurring in a tumor without known oncogene mutations (i.e., one candidate in the driver-negative subset).</td>
                        </tr>
                        <tr>
                            <td><strong>assay_and_platforms</strong></td>
                            <td>Whole-genome sequencing (paired-end and split-read mapping) to detect rearrangements; quantitative PCR (qPCR) used to validate the duplication breakpoint/structure.</td>
                        </tr>
                        <tr>
                            <td><strong>candidate_driver_event</strong></td>
                            <td>In-frame kinase domain duplication in SIK2 (salt-inducible kinase 2)</td>
                        </tr>
                        <tr>
                            <td><strong>event_class</strong></td>
                            <td>structural variant/rearrangement (in-frame duplication)</td>
                        </tr>
                        <tr>
                            <td><strong>genes_and_pathways_implicated</strong></td>
                            <td>SIK2 → AMPK-related kinase family; potentially connects to STK11/LKB1 signaling (activation site near Thr-175) and may influence metabolic/AMPK-related pathways rather than direct RTK/RAS/RAF signaling.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative_subset</strong></td>
                            <td>Reported as an individual event in the WGS subset in a tumor described as lacking canonical oncogene mutations; exact numerator/denominator not provided (appears to be a single case).</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_overall_luad</strong></td>
                            <td>Observed at least once among the 24 WGS cases; not reported across entire 183-sample cohort frequency.</td>
                        </tr>
                        <tr>
                            <td><strong>mutual_exclusivity_or_cooccurrence</strong></td>
                            <td>Specifically noted as occurring in a tumor without mutations in known lung adenocarcinoma oncogenes (i.e., mutually exclusive with canonical oncogene mutations in that case); broader co-occurrence patterns not reported.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type_for_driver_status</strong></td>
                            <td>Structural discovery by WGS with breakpoint mapping and qPCR validation; positional proximity of duplication to activation Thr-175 suggests a plausible activating effect; no recurrence or statistical significance beyond the single event is provided.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_validation</strong></td>
                            <td>No functional assays (transformation, phosphorylation, or drug-sensitivity) for the SIK2 duplication are reported in this paper beyond genomic validation by qPCR.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications_and_response</strong></td>
                            <td>No targeted therapy or sensitivity data provided; therapeutic implications are speculative (possible targeting of kinase activity if activating).</td>
                        </tr>
                        <tr>
                            <td><strong>omics_signatures_in_driver_negative_tumors</strong></td>
                            <td>No specific expression or pathway activation signature reported for the SIK2 event; paper generally notes that many tumors lack RTK/MAPK drivers and that alternative mechanisms (including kinase rearrangements) may underlie some driver-negative cases.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_signatures</strong></td>
                            <td>Not specified for the individual SIK2 case; cohort-wide mutation signatures stratified tumors into clusters that correlated with smoking history.</td>
                        </tr>
                        <tr>
                            <td><strong>histologic_or_clinical_associations</strong></td>
                            <td>None reported specifically for SIK2 event.</td>
                        </tr>
                        <tr>
                            <td><strong>alternative_explanations_or_limitations</strong></td>
                            <td>Single-case observation; lack of functional validation; WGS detection required — such events could be missed by WES or targeted panels; uncertain whether duplication is activating vs passenger.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_model</strong></td>
                            <td>Duplication encompassing the kinase domain and region upstream of Thr-175 could constitutively activate SIK2 (mimicking phosphorylation/activation) leading to oncogenic downstream signaling distinct from canonical RTK/RAS/RAF pathways.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e54.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e54.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ROCK1 dup</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ROCK1 multi-exon duplication (19-exon duplication)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A large in-frame duplication spanning ~19 exons of ROCK1 detected by WGS in a lung adenocarcinoma tumor without canonical oncogene mutations, proposed as a potential activating rearrangement affecting Rho/ROCK signaling.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Detected in the WGS subset of the 183-sample LUAD cohort (24 WGS); described among tumors lacking known oncogene mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>definition_of_driver_negative</strong></td>
                            <td>Driver-negative definition consistent with absence of canonical activating mutations or focal amplifications in known oncogenes; ROCK1 duplication reported in a tumor lacking such oncogene mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_fraction</strong></td>
                            <td>Not quantified; ROCK1 duplication described as an individual event in the WGS subset occurring in a tumor without canonical oncogene mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>assay_and_platforms</strong></td>
                            <td>Whole-genome sequencing with paired-end and split-read mapping to identify rearrangement; validation approach for this specific duplication not detailed beyond discovery (WGS).</td>
                        </tr>
                        <tr>
                            <td><strong>candidate_driver_event</strong></td>
                            <td>Large in-frame duplication of ROCK1 (19-exon duplication)</td>
                        </tr>
                        <tr>
                            <td><strong>event_class</strong></td>
                            <td>structural variant/rearrangement (in-frame multi-exon duplication)</td>
                        </tr>
                        <tr>
                            <td><strong>genes_and_pathways_implicated</strong></td>
                            <td>ROCK1 → Rho/ROCK signaling (serine/threonine kinase effector of Rho), implicated in cytoskeletal regulation, cell motility, and possibly invasion/metastasis pathways rather than canonical RTK/RAS/RAF.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative_subset</strong></td>
                            <td>Appears as a single discovery in the WGS subset; exact frequency among driver-negative tumors not provided.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_overall_luad</strong></td>
                            <td>Detected at least once among the WGS cases; overall cohort frequency not reported.</td>
                        </tr>
                        <tr>
                            <td><strong>mutual_exclusivity_or_cooccurrence</strong></td>
                            <td>Reported among tumors that lacked mutations in canonical lung adenocarcinoma oncogenes (i.e., found in a driver-negative tumor); no broader mutual exclusivity/co-occurrence statistics reported.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type_for_driver_status</strong></td>
                            <td>Structural WGS evidence of an in-frame duplication; biological plausibility given kinase domain involvement; no statistical recurrence shown.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_validation</strong></td>
                            <td>No functional assays or modeling are reported for the ROCK1 duplication in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications_and_response</strong></td>
                            <td>No therapy or drug-sensitivity data reported; potential therapeutic interest given ROCK1's kinase nature, but untested here.</td>
                        </tr>
                        <tr>
                            <td><strong>omics_signatures_in_driver_negative_tumors</strong></td>
                            <td>No specific signatures reported for this event.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_signatures</strong></td>
                            <td>Not specified for the individual case.</td>
                        </tr>
                        <tr>
                            <td><strong>histologic_or_clinical_associations</strong></td>
                            <td>Not reported.</td>
                        </tr>
                        <tr>
                            <td><strong>alternative_explanations_or_limitations</strong></td>
                            <td>Single-case finding without functional follow-up; small number of WGS samples limits ability to assess recurrence; WES would likely miss such events.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_model</strong></td>
                            <td>Duplication of multiple exons in ROCK1 could alter regulatory/kinase architecture and lead to constitutive ROCK1 activity, promoting oncogenic phenotypes (motility/invasion/proliferation) independently of RTK/RAS/RAF drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e54.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e54.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>U2AF1 p.S34F</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>U2AF1 Ser34Phe (p.S34F) hotspot mutation in U2AF1 (spliceosome factor)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Recurrent hotspot mutation (c.101C>T, p.S34F) in the splicing factor U2AF1 found in ~3% of cases, statistically significant and associated with reduced progression-free survival; first report of U2AF1 mutations in an epithelial tumor context within this study.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>183 lung adenocarcinomas (WES/WGS) analyzed; mutation discovered through exome sequencing and InVEx statistical analysis of functional impact.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>definition_of_driver_negative</strong></td>
                            <td>U2AF1 mutations are presented as potential driver events that may explain tumorigenesis in cases lacking canonical proliferative drivers (i.e., RTK/RAS/RAF-negative), since some U2AF1-mutant tumors lacked known oncogene mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_fraction</strong></td>
                            <td>U2AF1 nonsynonymous mutations occurred in ~3% of cases (5/183 approximately as reported); not all U2AF1-mutant tumors were driver-negative (one co-occurred with KRAS p.Q61H), but several occurred without known proliferation-sustaining oncogenes.</td>
                        </tr>
                        <tr>
                            <td><strong>assay_and_platforms</strong></td>
                            <td>Whole-exome sequencing (WES/WGS) for detection of coding SNVs; statistical InVEx (PolyPhen-2-based) to call significance; survival analysis performed on clinical data.</td>
                        </tr>
                        <tr>
                            <td><strong>candidate_driver_event</strong></td>
                            <td>Recurrent U2AF1 p.S34F hotspot missense mutation affecting core spliceosome factor</td>
                        </tr>
                        <tr>
                            <td><strong>event_class</strong></td>
                            <td>SNV/indel (recurrent missense hotspot)</td>
                        </tr>
                        <tr>
                            <td><strong>genes_and_pathways_implicated</strong></td>
                            <td>Spliceosome / RNA splicing machinery → implicates RNA processing and splicing deregulation as an alternative oncogenic mechanism (epigenetic/RNA deregulation hallmark). Not RTK/RAS/RAF-related.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative_subset</strong></td>
                            <td>Observed in 4–5 cases overall (3%); several of these did not have canonical oncogene drivers, making it a candidate driver in a subset of driver-negative tumors (exact numerator of U2AF1-only driver-negative tumors not specified).</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_overall_luad</strong></td>
                            <td>3% of cohort (as reported).</td>
                        </tr>
                        <tr>
                            <td><strong>mutual_exclusivity_or_cooccurrence</strong></td>
                            <td>One U2AF1 p.S34F occurred together with KRAS p.Q61H (co-occurrence), indicating that U2AF1 mutations can co-occur with canonical drivers though some occur independently. U2AF1 mutations co-occurred statistically with NF1 mutations (p = 0.0011).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type_for_driver_status</strong></td>
                            <td>Statistical enrichment (PPH2 InVEx p = 2.0 × 10^-6), recurrent identical hotspot (p.S34F seen in 4 of 5 cases), analogy to recurrent U2AF1 hotspot in myelodysplastic syndrome, and association with reduced progression-free survival (log-rank p = 0.00011).</td>
                        </tr>
                        <tr>
                            <td><strong>functional_validation</strong></td>
                            <td>No direct functional assays reported in this paper for lung adenocarcinoma; functional relevance inferred from recurrence, hotspot identity, and analogy to hematologic malignancies where the same mutation is recurrent.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications_and_response</strong></td>
                            <td>No therapeutic targeting or drug-sensitivity data provided here; the implication is that spliceosome perturbation could define a biologic subset, but therapeutic approaches are not tested in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>omics_signatures_in_driver_negative_tumors</strong></td>
                            <td>The paper suggests that mutations in splicing factors (including U2AF1) implicate an 'epigenetic and RNA deregulation' hallmark but does not provide specific transcriptomic/splicing signatures for these tumors within this study.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_signatures</strong></td>
                            <td>U2AF1-mutant cases were among the cohort and contributed to mutation-spectrum analyses; no specific TMB distinctions for U2AF1-mutant driver-negative tumors are provided.</td>
                        </tr>
                        <tr>
                            <td><strong>histologic_or_clinical_associations</strong></td>
                            <td>U2AF1 mutations (in the four patients with survival data) were associated with significantly reduced progression-free survival. No smoking or histologic associations specified beyond that.</td>
                        </tr>
                        <tr>
                            <td><strong>alternative_explanations_or_limitations</strong></td>
                            <td>Functional consequences in epithelial contexts are inferred (analogy to MDS) but not directly shown; some U2AF1 mutants co-occur with known oncogenes complicating assignment of driver status; limited case numbers.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_model</strong></td>
                            <td>Recurrent hotspot mutation in U2AF1 alters splice site recognition / splicing fidelity, leading to aberrant splicing of genes important for tumorigenesis (RNA deregulation as a contributing oncogenic mechanism).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e54.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e54.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>RBM10 truncations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>RBM10 truncating mutations (nonsense, frameshift, splice-site)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Recurrent truncating, presumably loss-of-function mutations in the RNA-binding protein RBM10 (7% of cases), enriched for nonsense/frameshift/splice-site events and nominated as a candidate tumor suppressor in LUAD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>183 lung adenocarcinomas analyzed by WES/WGS; RBM10 mutations discovered in exome data and evaluated by InVEx.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>definition_of_driver_negative</strong></td>
                            <td>RBM10 truncating events are proposed as potential drivers/tumor suppressor alterations that may contribute to tumorigenesis in tumors lacking canonical proliferative oncogenes; RBM10-mutant tumors sometimes co-occurred with known oncogenes.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_fraction</strong></td>
                            <td>RBM10 was mutated in 12/183 cases (~7% overall); the fraction of RBM10 mutations that occurred in otherwise driver-negative tumors is not fully enumerated, though co-occurrence with known oncogenes was observed.</td>
                        </tr>
                        <tr>
                            <td><strong>assay_and_platforms</strong></td>
                            <td>WES/WGS for detection of SNVs/indels; InVEx PPH2 statistical analysis to nominate significance; mutation types annotated (truncating vs others).</td>
                        </tr>
                        <tr>
                            <td><strong>candidate_driver_event</strong></td>
                            <td>Recurrent truncating (loss-of-function) mutations in RBM10</td>
                        </tr>
                        <tr>
                            <td><strong>event_class</strong></td>
                            <td>SNV/indel causing truncation (nonsense, frameshift, splice-site) → loss-of-function</td>
                        </tr>
                        <tr>
                            <td><strong>genes_and_pathways_implicated</strong></td>
                            <td>RNA binding / splicing regulation → implicates RNA processing and epigenetic/RNA deregulation hallmark (non-RTK pathway).</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative_subset</strong></td>
                            <td>12/183 overall (7%); several RBM10-mutant tumors co-occurred with KRAS, EGFR, and PIK3CA, so precise frequency among driver-negative tumors is not specified.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_overall_luad</strong></td>
                            <td>7% of cohort (12/183).</td>
                        </tr>
                        <tr>
                            <td><strong>mutual_exclusivity_or_cooccurrence</strong></td>
                            <td>RBM10 mutations co-occurred with known lung adenocarcinoma oncogenes (KRAS, EGFR, and PIK3CA) in some cases, indicating non-exclusive distribution with canonical drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type_for_driver_status</strong></td>
                            <td>Significant enrichment of truncating mutations detected by PPH2 InVEx (p = 0.00042 for RBM10 in global analysis) and recurrent truncating event pattern consistent with tumor suppressor inactivation.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_validation</strong></td>
                            <td>No functional experiments for RBM10 performed in this study; nomination based on statistical enrichment and mutation types.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications_and_response</strong></td>
                            <td>No direct therapeutic implications or drug-sensitivity data provided; suggests RNA/splicing regulatory mechanisms may be targetable in principle but not explored here.</td>
                        </tr>
                        <tr>
                            <td><strong>omics_signatures_in_driver_negative_tumors</strong></td>
                            <td>Paper groups RBM10 with other splice/epigenetic regulators and proposes an epigenetic/RNA deregulation hallmark; specific transcriptome alterations for RBM10 mutants not shown.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_signatures</strong></td>
                            <td>Not specified for RBM10-mutant tumors specifically.</td>
                        </tr>
                        <tr>
                            <td><strong>histologic_or_clinical_associations</strong></td>
                            <td>RBM10 mutations did not show a clear association with clinical variables or mutation spectrum in this study (noted in figure legend).</td>
                        </tr>
                        <tr>
                            <td><strong>alternative_explanations_or_limitations</strong></td>
                            <td>Co-occurrence with canonical oncogenes in some cases complicates causal assignment; lack of functional validation; possibility of passenger truncations though truncation-enrichment argues for selection.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_model</strong></td>
                            <td>Loss of RBM10 function perturbs RNA processing/splicing programs that contribute to oncogenesis, fitting within a proposed 'epigenetic and RNA deregulation' hallmark rather than RTK/RAS/RAF activation.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e54.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e54.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed or discovered driver alterations/mechanisms in lung adenocarcinoma cases described as driver-negative/oncogene-negative/unknown-driver (often RTK/RAS/RAF-negative), including the evidence supporting driver status and any therapeutic or functional validation.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ARID1A truncations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ARID1A truncating mutations (SWI/SNF chromatin-remodeling subunit)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Recurrent truncating mutations in ARID1A (8% of cases) resulting in loss-of-function consistent with perturbation of chromatin remodeling and nomination as a tumor suppressor in LUAD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cohort_description</strong></td>
                            <td>Identified in the 183 LUAD cohort (WES/WGS) using InVEx LOF analysis and CGC-focused tests; ARID1A alterations reported alongside other epigenetic regulators.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>definition_of_driver_negative</strong></td>
                            <td>ARID1A truncations are proposed as alternative mechanisms (epigenetic deregulation) that may contribute to tumorigenesis in tumors lacking canonical RTK/RAS/RAF drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>driver_negative_fraction</strong></td>
                            <td>ARID1A mutated in ~8% of cases (exact count reported as 8%); paper does not specify how many ARID1A-mutant tumors were otherwise driver-negative.</td>
                        </tr>
                        <tr>
                            <td><strong>assay_and_platforms</strong></td>
                            <td>WES/WGS detection of coding mutations; LOF InVEx analysis to test enrichment of truncating events; cancer gene census (CGC) focused analysis.</td>
                        </tr>
                        <tr>
                            <td><strong>candidate_driver_event</strong></td>
                            <td>Truncating (loss-of-function) mutations in ARID1A</td>
                        </tr>
                        <tr>
                            <td><strong>event_class</strong></td>
                            <td>SNV/indel causing truncation (nonsense, frameshift) → loss-of-function</td>
                        </tr>
                        <tr>
                            <td><strong>genes_and_pathways_implicated</strong></td>
                            <td>Chromatin remodeling (SWI/SNF complex) → epigenetic deregulation pathway (not RTK/RAS/RAF).</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative_subset</strong></td>
                            <td>8% of overall cohort; fraction specifically among driver-negative tumors not explicitly provided.</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_overall_luad</strong></td>
                            <td>8% of cohort (as reported).</td>
                        </tr>
                        <tr>
                            <td><strong>mutual_exclusivity_or_cooccurrence</strong></td>
                            <td>Co-occurrence patterns not specified in detail; ARID1A included in the set of epigenetic regulators mutated across cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type_for_driver_status</strong></td>
                            <td>Enrichment of truncating mutations evaluated by CGC LOF InVEx (p = 0.027), recurrent truncation pattern consistent with selection for loss-of-function.</td>
                        </tr>
                        <tr>
                            <td><strong>functional_validation</strong></td>
                            <td>No ARID1A-specific functional assays reported in this paper; nomination based on statistical enrichment and known biology of SWI/SNF subunits as tumor suppressors.</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications_and_response</strong></td>
                            <td>Not explored in this study; suggests possible targeting of vulnerabilities from chromatin remodeling loss but no data provided.</td>
                        </tr>
                        <tr>
                            <td><strong>omics_signatures_in_driver_negative_tumors</strong></td>
                            <td>The paper groups ARID1A with epigenetic regulators and proposes an additional hallmark of epigenetic and RNA deregulation; no direct transcriptome or chromatin data for ARID1A mutants reported here.</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_mutational_burden_and_signatures</strong></td>
                            <td>Not reported specifically for ARID1A-mutant tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>histologic_or_clinical_associations</strong></td>
                            <td>Not specifically reported for ARID1A in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>alternative_explanations_or_limitations</strong></td>
                            <td>Statistical nomination and truncation enrichment argue for selection but functional validation is lacking; contribution of ARID1A loss to proliferative signaling vs other hallmarks is indirect.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_model</strong></td>
                            <td>Loss of ARID1A impairs SWI/SNF-mediated chromatin remodeling, leading to epigenetic dysregulation of gene expression programs that promote tumorigenesis in a subset of LUADs lacking canonical RTK/RAS/RAF drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies <em>(Rating: 2)</em></li>
                <li>A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing <em>(Rating: 2)</em></li>
                <li>ROS1 rearrangements define a unique molecular class of lung cancers <em>(Rating: 2)</em></li>
                <li>RET, ROS1 and ALK fusions in lung cancer <em>(Rating: 2)</em></li>
                <li>Somatic mutations affect key pathways in lung adenocarcinoma <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>